Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7Sarcoma 5Lymphoid 1

Conditions

Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Lymphoma, Non-Hodgkin 3Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Oropharyngeal Neoplasms 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Neutrophilic, Chronic 1

Interventions

Temozolomide 9Filgrastim 7Specimen Handling 6X-Rays 5Rituximab 5Radiotherapy 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Psychiatric Rehabilitation 4Nuclear Medicine Department, Hospital 4Methotrexate 4Etoposide 4Cyclophosphamide 4Biopsy 4etoposide phosphate 3Pemetrexed 3Melphalan 3Cytarabine 3Carboplatin 3tazemetostat 2sargramostim 2olaparib 2larotrectinib 2erdafitinib 2ensartinib 2Vincristine 2Vemurafenib 2Topotecan 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × motexafin gadolinium × Lymphoid × Clear all
NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Northwestern University

Phase EARLY_PHASE1 Withdrawn
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡